Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and -haemolytic streptococci collected from western European countries in 2011

Morrissey, I., Seifert, H., Canton, R., Nordmann, P., Stefani, S., MacGowan, A., Janes, R. and Knight, D.ORCID: 0000-0002-9480-4733 (2013) Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and -haemolytic streptococci collected from western European countries in 2011. Journal of Antimicrobial Chemotherapy, 68 (1). pp. 164-167.

Link to Published Version: https://doi.org/10.1093/jac/dks344
*Subscription may be required

Abstract

Objectives

To determine the activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci (VRE) and β-haemolytic streptococci recently isolated from acute bacterial skin and skin structure infections or bacteraemia in western Europe.

Methods

Forty-one centres in Spain (8), Italy (9), Germany (8), France (8) and the UK (8) submitted 866 isolates [204 methicillin-resistant Staphylococcus aureus (MRSA), 177 methicillin-resistant coagulase-negative staphylococci (MRCoNS), 101 VRE, 193 Streptococcus agalactiae and 191 Streptococcus pyogenes] that were collected during the first 6 months of 2011. These were re-identified and susceptibilities to oritavancin and comparators were determined.

Results

Oritavancin was very active against MRSA (MIC50/MIC90 0.03/0.06 mg/L), MRCoNS (0.06/0.12 mg/L), VRE (0.03/0.06 mg/L), S. agalactiae (0.03/0.06 mg/L) and S. pyogenes (0.06/0.25 mg/L). The highest oritavancin MIC observed was 0.25 mg/L (species were S. aureus, Staphylococcus epidermidis, Staphylococcus hominis, S. agalactiae, S. pyogenes and Enterococcus faecalis).

Conclusions

These data from recently collected Gram-positive bacteria in western Europe confirm the potent in vitro activity of oritavancin against a wide range of resistant MRSA, MRCoNS and VRE isolates, including ones resistant to newer agents.

Item Type: Journal Article
Publisher: Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy
Copyright: © The Author 2012
URI: http://researchrepository.murdoch.edu.au/id/eprint/45410
Item Control Page Item Control Page